EUVIMEDEUVIMED entdecken
Multizentrische StudieOpen Access · CC BY 4.0

A Real‐World Analysis of Outcomes in CIC‐Rearranged Sarcomas: A Canadian Sarcoma Research and Clinical Collaboration (CanSaRCC) Study

Talya Wittmann Dayagi, Hagit Peretz Soroka, Alannah Smrke, Rebecca J Deyell iD, Xiaolan Feng, Sapna Oberoi iD, Shantanu Banerji, Jonathan Noujaim, Nicolas Prud'homme, Ramy Saleh, Omar Farooq Khan iD, Jonathan Willard Bush iD und 6 weitere

Cancer Medicine · 2026

DOI: 10.1002/cam4.71495 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Cancer Medicine, 2026. Verfasst von Talya Wittmann Dayagi und 17 weiteren Autor:innen. Beteiligte Einrichtung: Division of Haematology and Oncology, Department of Pediatrics, the Hospital for Sick Children, University of Toronto, Toronto, Ontario, Canada. Hauptthemen laut MEDLINE: Sarcoma, Gene Rearrangement. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 27 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

CIC‐rearranged sarcomas (CRS) are rare tumors predominantly affecting young adults. Despite distinct biology, CRS are often treated like Ewing sarcomas with multi‐agent chemotherapy, surgery, and radiotherapy, although the benefits of each remain unclear. We report the impact of treatment on response and survival.

Methods

This retrospective multicenter study included patients diagnosed with CRS between 2002 and 2023. Demographic, treatment, and outcome data were collected. Event‐free (EFS) and overall survival (OS) were estimated using Kaplan–Meier analysis; risk factors were assessed via log‐rank tests and Cox regression. Treatment response was assessed using RECIST.

Results

Among 27 patients (median age 21.5 years; range 8–83), 14 (52%) had localized and 12 (44%) metastatic disease (1 unknown). In the localized group, 6 (43%) received chemotherapy (Response: 2 complete, CR; 1 partial, PR; 1 mixed, MR; 1 stable, SD; 1 progressive disease, PD); 5 (36%) died—3 (21%) had received chemotherapy. Among metastatic patients, 10 (83%) received chemotherapy (1 CR, 5 PR, 2 MR, 1 PD); 9 died (one without chemotherapy). Local control was achieved in 12/14 (86%) localized and 7/12 (56%) metastatic patients. Only surgical resection was associated with improved OS (HR 0.13; p < 0.01) and EFS (HR 0.26; p < 0.01), particularly with R0 resection (EFS HR 0.23; p = 0.02). At median follow‐up of 18 months, 2‐year EFS was 56% vs. 8% ( p = 0.02) and OS was 67% vs. 23% ( p = 0.02) for localized vs. metastatic disease.

Conclusion

Complete resection is critical in CRS. Chemotherapy benefit remains uncertain, underscoring the need for improved local control and novel, biology‐driven therapies.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

SarcomaGene RearrangementHumansMaleFemaleAdolescentAdultMiddle AgedYoung AdultRetrospective StudiesChildAgedAged, 80 and overCanadaTreatment OutcomeCombined Modality TherapyRepressor Proteins

Stichwörter der Autor:innen

CIC‐rearranged sarcomaEwing‐like sarcomaadolescent and young adult oncologychemotherapy responsemetastatic sarcomasoft‐tissue sarcomasurgical resection

Substanzen

CIC protein, humanRepressor Proteins

Autor:innen und Institutionen

  • Division of Haematology and Oncology, Department of Pediatrics, the Hospital for Sick Children, University of Toronto, Toronto, Ontario, Canada.
  • Division of Medical Oncology, Princess Margaret Cancer Centre, University of Toronto, Toronto, Ontario, Canada.
  • Department of Medical Oncology, BC Cancer, University of British Columbia, Vancouver, British Columbia, Canada.
  • Division of Pediatric Hematology/Oncology/BMT, B.C. Children's Hospital and Research Institute, University of British Columbia, Vancouver, British Columbia, Canada.
  • Division of Medical Oncology, Tom Baker Cancer Center, Calgary, Alberta, Canada.
  • Arthur Child Comprehensive Cancer Centre, Calgary, Alberta, Canada.

ORCID-Profile: Rebecca J Deyell, Sapna Oberoi, Omar Farooq Khan, Jonathan Willard Bush, Geoffrey Watson, Abha Anshu Gupta, Jack Brzezinski

Zitieren

APA

Wittmann Dayagi, T., Peretz Soroka, H., Smrke, A., Deyell, R. J., Feng, X., Oberoi, S., Banerji, S., Noujaim, J., Prud'homme, N., Saleh, R., Khan, O. F., Bush, J. W., Marwa, B., Watson, G., Holloway, C., Zhang, L., Gupta, A. A., & Brzezinski, J. (2026). A Real‐World Analysis of Outcomes in CIC‐Rearranged Sarcomas: A Canadian Sarcoma Research and Clinical Collaboration (CanSaRCC) Study. Cancer Medicine. https://doi.org/10.1002/cam4.71495

Vancouver

Wittmann Dayagi T, Peretz Soroka H, Smrke A, Deyell RJ, Feng X, Oberoi S, et al. A Real‐World Analysis of Outcomes in CIC‐Rearranged Sarcomas: A Canadian Sarcoma Research and Clinical Collaboration (CanSaRCC) Study. Cancer Medicine. 2026. doi:10.1002/cam4.71495

BibTeX
@article{WittmannDayagi2026,
  author = {Wittmann Dayagi, Talya and Peretz Soroka, Hagit and Smrke, Alannah and Deyell, Rebecca J and Feng, Xiaolan and Oberoi, Sapna and Banerji, Shantanu and Noujaim, Jonathan and Prud'homme, Nicolas and Saleh, Ramy and Khan, Omar Farooq and Bush, Jonathan Willard and Marwa, Bilal and Watson, Geoffrey and Holloway, Caroline and Zhang, Lingxin and Gupta, Abha Anshu and Brzezinski, Jack},
  title = {A Real‐World Analysis of Outcomes in CIC‐Rearranged Sarcomas: A Canadian Sarcoma Research and Clinical Collaboration (CanSaRCC) Study},
  journal = {Cancer Medicine},
  year = {2026},
  doi = {10.1002/cam4.71495}
}
Kostenlos starten →